A big discussion is taking up space in the pharma industry today, centered on the gross-to-net bubble. For the past twenty years CCOs, brand leads, and pricing strategists who manage physician-administered, infused, and injected pharmaceuticals have been operating under a government-designed reimbursement framework built for stability, transparency, and resistance to the structural list-price inflation that bloated the pharmacy benefit side of the ledger. This architecture worked exactly as designed.

Until now.

In Bill Roth’s newest series with Pharmaceutical Executive, he discusses the latest phenomenon he and the IntegriChain C&A practice see on the horizon: the Medical Benefit Bubble. Read this first entry, where Bill ponders what causes the WAC and ASP 1:1 ratio to drift and create this bubble.